Literature DB >> 27016232

Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence.

Adnan Munkarah1, Ismail Mert2, Jasdeep Chhina3, Suhail Hamid4, Laila Poisson5, Sharon Hensley-Alford6, Shailendra Giri7, Ramandeep Rattan8.   

Abstract

OBJECTIVES: Adipocyte derived free fatty acids (FFA) promote epithelial ovarian cancer (EOC) by acting as a fuel source to support the energy requirement of the cancer cells. FFA may also exert biological effects through signaling pathways. Recently, a family of FFA activated G-protein coupled receptors (FFAR/GPCRs) was identified. Our objective was to investigate the role of FFAR/GPCRs in EOC and assess their potential as therapeutic targets.
METHODS: The mRNA (RT-PCR) expression of FFAR/GPCR family members (FFAR1/GPR40; FFAR2/GPR43, FFAR3/GPR41, FFAR4/GPR120 and GPR84) was examined in: (1) a syngeneic mouse model of EOC fed high energy diet (60% fat) or regular diet (30% fat), (2) EOC cell lines exposed to free fatty acids and (3) specimens from 13 histologically normal ovaries and 28 high grade ovarian serous carcinomas. The GPR 40 antagonist, GW1100, was used to inhibit FFAR1/GPR40 and cell survival was assayed by MTT in various cell lines.
RESULTS: High Grade Serous carcinoma specimens expressed significantly increased GPR40 compared to normal ovaries (p=0.0020). Higher expression was noted in advanced stage disease. ID8 ovarian tumors from mice fed with high fat diet also showed higher GPR40 expression. Exposing EOC cells to FFAs, increased GPR40 expression. Treatment of EOC cell lines with GW100 resulted in growth inhibition and was associated with an alteration in their energy metabolism.
CONCLUSION: FFA-induced cancer cell growth may be partly mediated through FFAR1/GPR40. Targeting of FFAR1/GPR40 may be an attractive treatment strategy in EOC, and possibly offers a targeted treatment for a subset of EOC patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27016232     DOI: 10.1016/j.ygyno.2016.02.026

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  Serum Free Fatty Acids and G-Coupled Protein Receptors Are Associated With the Prognosis of Epithelial Ovarian Cancer.

Authors:  Lili Zhang; Xiangzhong Zhao; Huijun Chu; Han Zhao; Xiaoying Lai; Jing Li; Teng Lv
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

Review 2.  Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines.

Authors:  Riya Khetan; Cintya Dharmayanti; Todd A Gillam; Eric Kübler; Manuela Klingler-Hoffmann; Carmela Ricciardelli; Martin K Oehler; Anton Blencowe; Sanjay Garg; Hugo Albrecht
Journal:  Cancers (Basel)       Date:  2022-05-10       Impact factor: 6.575

3.  Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.

Authors:  Shuai Liu; Mingwei Gao; Xiaoqing Wang; Sentai Ding; Jiaju Lv; Dexuan Gao; Zhiyang Wang; Zhihong Niu
Journal:  Oncotarget       Date:  2016-11-29

Review 4.  Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment?

Authors:  Jesús Cosín-Roger; Dolores Ortiz-Masia; Maria Dolores Barrachina; Sara Calatayud
Journal:  Cells       Date:  2020-10-23       Impact factor: 6.600

Review 5.  A review of non-prostanoid, eicosanoid receptors: expression, characterization, regulation, and mechanism of action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2021-06-26       Impact factor: 5.782

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.